• Moesin as a Biomarker of Endothelial Injury in Sepsis Models

  2026-04-28

  Chen et al. identify moesin as a novel, clinically relevant biomarker for endothelial injury in sepsis, establishing its correlation with disease severity and elucidating its mechanistic involvement in barrier dysfunction through the Rock1/MLC and NF-κB pathways. These findings offer a new molecular handle for both basic and translational research in vascular pathology and biomarker development.

• Cell lysis buffer for WB and IP: Optimizing Chemoresistance

  2026-04-28

  Unlock robust, reproducible protein extraction for Western blot and immunoprecipitation in chemoresistance studies using APExBIO's Cell lysis buffer for WB and IP. This buffer's unique inhibitor cocktail preserves native interactions, enabling advanced workflows that dissect tumor microenvironment dynamics and protein signaling.

• Oleanolic Acid in Dual-Loaded Liposome Assays: iNOS Inductio

  2026-04-27

  Oleanolic acid's unique ability to induce iNOS and modulate COX-2 positions it as a cornerstone compound for dual-loaded liposome workflows targeting antiviral and immune pathways. This guide translates recent encapsulation efficiency breakthroughs into actionable protocols and troubleshooting strategies for maximizing reproducibility with APExBIO's high-purity oleanolic acid.

• FLAG tag Peptide (DYKDDDDK): Structural Precision and Protoc

  2026-04-27

  Explore the FLAG tag Peptide (DYKDDDDK) as a high-specificity protein expression tag, with unique insights into its structural compatibility and protocol optimization. This article provides advanced guidance for recombinant protein detection while integrating the latest structural findings and best practices.

• SB 431542 (A8249): Reliable ALK5 Inhibitor for TGF-β Assays

  2026-04-26

  SB 431542 (SKU A8249) is a highly selective ALK5 inhibitor that enables rigorous control of TGF-β/Smad signaling in cell-based and in vivo assays. This article addresses real-world laboratory challenges—from assay reproducibility to vendor selection—and demonstrates how SB 431542 supports robust, data-driven research outcomes.

• Cediranib (AZD2171): Applied Angiogenesis Inhibition in Canc

  2026-04-25

  Cediranib (AZD2171) empowers researchers to dissect VEGFR-driven angiogenesis with unparalleled selectivity and quantitative precision. This guide translates advanced in vitro methodologies and troubleshooting insights into practical workflows, maximizing reproducibility and data depth for next-generation cancer biology studies.

• Indometacin Sodium: Bridging Mechanism and Translation in In

  2026-04-24

  This thought-leadership article explores how Indometacin Sodium Trihydrate advances translational inflammation research. By integrating mechanistic clarity, validated protocols, and clinical parallels, we guide researchers on leveraging its COX inhibition, Wnt/β-catenin modulation, and unique workflow versatility. We connect evidence from recent clinical and preclinical studies, provide actionable experimental guidelines, and articulate the strategic significance for investigators navigating anti-inflammatory, pain, and neuroregenerative domains.

• Boc-D-FMK: Pan-Caspase Inhibitor Workflows for Apoptosis Res

  2026-04-24

  Boc-D-FMK, a cell-permeable pan-caspase inhibitor from APExBIO, delivers consistent, broad-spectrum apoptosis inhibition across cell and animal models. This guide details validated protocols, advanced use-cases, and troubleshooting strategies to maximize experimental precision in inflammation and cell death research.

• Transmission Dynamics of Carbapenemase Genes in CREC: Insigh

  2026-04-23

  This study provides a detailed molecular and epidemiological characterization of carbapenemase-encoding gene (CEG) distribution and transmission in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong, China during the COVID-19 pandemic. Findings highlight high rates of multidrug resistance, predominant mobile genetic elements, and the efficient horizontal transfer of resistance genes, informing future antimicrobial resistance research and laboratory modeling.

• SAG: Smoothened Receptor Agonist for Advanced Hedgehog Pathw

  2026-04-23

  Smoothened Agonist (SAG) delivers potent, selective activation of the Hedgehog pathway—enabling robust myelin regeneration, neuroprotection, and mitochondrial rescue in translational models. This guide unpacks SAG's innovative workflows, troubleshooting strategies, and pivotal findings from referenced literature to help researchers maximize experimental reliability and cross-domain impact.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-04-22

  This study elucidates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids in mice. The findings highlight disease-induced variability in drug exposure and provide a framework for optimizing therapeutic regimens in MASLD/MASH contexts.

• YTHDF1 Phase Separation Drives SSC Fate via IkB-NF-kB-CCND1

  2026-04-22

  Fang et al. (2023) reveal how YTHDF1-driven liquid-liquid phase separation (LLPS) is essential for the transdifferentiation of spermatogonial stem cells (SSCs) by activating the IkB-NF-kB-CCND1 axis. These findings elucidate a translational regulatory mechanism of cell fate transitions and provide a foundation for future stem cell and neurobiology research.

• NU7441 (KU-57788) DNA-PK Inhibitor: Deep Insights for DDR an

  2026-04-21

  Explore the advanced scientific applications of NU7441 (KU-57788) in DNA repair research, oncology, and emerging HIV latency models. This cornerstone article delivers unique insights into DNA-PK inhibition, bridging cancer and HIV reservoir studies for next-generation assay design.

• Redefining In Vitro Drug Response: Insights from Schwartz et

  2026-04-21

  Schwartz et al. introduce a refined in vitro framework distinguishing between proliferative arrest and cell death in cancer drug evaluation. Their findings highlight the importance of distinct viability metrics for more accurate interpretation of anti-angiogenic and cytotoxic drug effects, with direct implications for translational oncology research.

• Trifluoperazine 2HCl: Applied Protocols for Dopamine D2 Inhi

  2026-04-20

  Trifluoperazine 2HCl stands out as a benchmark dopamine D2 receptor inhibitor, streamlining both neuropharmacology and immunology workflows. This guide delivers actionable protocols, advanced troubleshooting, and workflow enhancements—helping researchers maximize experimental reproducibility and cross-domain impact.

451 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page